Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naive HIV-1 Infected Subjects

Next Previous
Trial Profile

A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naive HIV-1 Infected Subjects

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir/ritonavir (Primary) ; Lamivudine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ANDES

Most Recent Events

  • 02 Aug 2022 Results from final results (first step/second step) at week 48 are presented at the 24th International AIDS Conference
  • 01 Aug 2018 Status changed from active, no longer recruiting to completed.
  • 07 Mar 2018 Primary endpoint (Percentage of patients with HIV-1 RNA levels of less than 50 copies/mL at week 48: non-inferiority of DRV/RTV plus 3TC with standard of care triple drug regimen with ritonavir-bosted Darunavir in FDC plus TDF/3TC) has been met, according to results of week 48, presented at the 25th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top